Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types.

Authors

• Sri Lekha Tummalapalli
• Julio Lamprea Montealegre
• Neil Warnock
• Michael Green
• Said A Ibrahim
• Michelle M Estrella

Publication/Presentation Date

12-1-2021

Abstract

This cross-sectional study evaluates the stipulations of coverage under commercial, health insurance exchange, Veterans Affairs, Medicare, Medicaid, or other insurance for canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.

Volume

2

Issue

12

First Page

214205

Last Page

214205

ISSN

2689-0186

Published In/Presented At

Tummalapalli, S. L., Montealegre, J. L., Warnock, N., Green, M., Ibrahim, S. A., & Estrella, M. M. (2021). Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types. JAMA health forum, 2(12), e214205. https://doi.org/10.1001/jamahealthforum.2021.4205

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

35977296

Department(s)

Administration and Leadership

Document Type

Article